251 related articles for article (PubMed ID: 30790468)
1. The role of chemotherapy in the treatment of stage II nasopharyngeal carcinoma: Retrospective analysis of the national cancer database.
Ahmed Z; Kujtan L; Kennedy K; Wood V; Schomas D; Subramanian J
Cancer Med; 2019 Apr; 8(4):1500-1507. PubMed ID: 30790468
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
Li PJ; Mo HY; Luo DH; Hu WH; Jin T
Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
[TBL] [Abstract][Full Text] [Related]
3. The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
Zeng YY; Xiang ZZ; He T; Liu F; Shao BF; Yan RN; Ma JC; Wang XR; Liu L
Oral Oncol; 2020 Dec; 111():104924. PubMed ID: 32736209
[TBL] [Abstract][Full Text] [Related]
4. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
Wei Z; Zhang Z; Luo J; Li N; Peng X
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
[TBL] [Abstract][Full Text] [Related]
5. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
[TBL] [Abstract][Full Text] [Related]
6. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial.
Chen QY; Wen YF; Guo L; Liu H; Huang PY; Mo HY; Li NW; Xiang YQ; Luo DH; Qiu F; Sun R; Deng MQ; Chen MY; Hua YJ; Guo X; Cao KJ; Hong MH; Qian CN; Mai HQ
J Natl Cancer Inst; 2011 Dec; 103(23):1761-70. PubMed ID: 22056739
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors of chemotherapy use in stage II nasopharyngeal carcinoma: A retrospective cohort study.
Pan XB; Huang ST; Chen KH; Jiang YM; Zhu XD
Medicine (Baltimore); 2019 Feb; 98(7):e14512. PubMed ID: 30762786
[TBL] [Abstract][Full Text] [Related]
8. Meta-Analysis on Induction Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma.
Mané M; Benkhaled S; Dragan T; Paesmans M; Beauvois S; Lalami Y; Szturz P; Gaye PM; Vermorken JB; Van Gestel D
Oncologist; 2021 Jan; 26(1):e130-e141. PubMed ID: 32924198
[TBL] [Abstract][Full Text] [Related]
9. A Comprehensive Analysis of Treatment Management and Survival Outcomes in Nasopharyngeal Carcinoma.
Goshtasbi K; Lehrich BM; Birkenbeuel JL; Abiri A; Harris JP; Kuan EC
Otolaryngol Head Neck Surg; 2021 Jul; 165(1):93-103. PubMed ID: 33231508
[TBL] [Abstract][Full Text] [Related]
10. Benefit of chemotherapy in stage III nasopharyngeal carcinoma: Analysis of the surveillance, epidemiology, and end results database.
Xiang ZF; Hu DF; Xiong HC; Li MY; Zhang ZC; Shen ED; Li WZ; Xiang YQ
Oral Oncol; 2021 Jun; 117():105284. PubMed ID: 33845238
[TBL] [Abstract][Full Text] [Related]
11. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial.
Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J; Sun Y
Int J Cancer; 2019 Jul; 145(1):295-305. PubMed ID: 30613964
[TBL] [Abstract][Full Text] [Related]
12. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.
Kong L; Zhang Y; Hu C; Guo Y; Lu JJ
Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641
[TBL] [Abstract][Full Text] [Related]
13. Induction Chemotherapy Followed by Radiotherapy versus Concurrent Chemoradiotherapy in elderly patients with nasopharyngeal carcinoma: finding from a propensity-matched analysis.
Zeng Q; Wang J; Lv X; Li J; Yin LJ; Xiang YQ; Guo X
BMC Cancer; 2016 Aug; 16(1):693. PubMed ID: 27577729
[TBL] [Abstract][Full Text] [Related]
14. Superiority of intensity-modulated radiation therapy in nasopharyngeal carcinoma with skull-base invasion.
Liao S; Xie Y; Feng Y; Zhou Y; Pan Y; Fan J; Mi J; Qin X; Yao D; Jiang W
J Cancer Res Clin Oncol; 2020 Feb; 146(2):429-439. PubMed ID: 31677113
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma.
Setakornnukul J; Thephamongkhol K
BMC Cancer; 2018 Mar; 18(1):329. PubMed ID: 29587665
[TBL] [Abstract][Full Text] [Related]
16. The effect of adjuvant chemotherapy on survival in patients with residual nasopharyngeal carcinoma after undergoing concurrent chemoradiotherapy.
Yang S; Lin S; Fu Q; Cai B; Kong F; Huang G; Li F; Wang H
PLoS One; 2015; 10(3):e0120019. PubMed ID: 25799566
[TBL] [Abstract][Full Text] [Related]
17. Improved overall survival is associated with adjuvant chemotherapy after definitive concurrent chemoradiotherapy for N3 nasopharyngeal cancer.
Tsai MH; Wu SY; Lu HH; Yu T; Tsai ST; Wu YH
Sci Rep; 2022 Aug; 12(1):13390. PubMed ID: 35927415
[TBL] [Abstract][Full Text] [Related]
18. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response.
Liu SL; Sun XS; Yan JJ; Chen QY; Lin HX; Wen YF; Guo SS; Liu LT; Xie HJ; Tang QN; Liang YJ; Li XY; Lin C; Du YY; Yang ZC; Xiao BB; Yang JH; Tang LQ; Guo L; Mai HQ
Radiother Oncol; 2019 Aug; 137():83-94. PubMed ID: 31078941
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a novel MR imaging predictor of response to induction chemotherapy in locoregionally advanced nasopharyngeal cancer: a randomized controlled trial substudy (NCT01245959).
Dong D; Zhang F; Zhong LZ; Fang MJ; Huang CL; Yao JJ; Sun Y; Tian J; Ma J; Tang LL
BMC Med; 2019 Oct; 17(1):190. PubMed ID: 31640711
[TBL] [Abstract][Full Text] [Related]
20. Local regression and control of T1-2 nasopharyngeal carcinoma treated with intensity-modulated radiotherapy.
Xue F; Ou D; Hu C; He X
Cancer Med; 2018 Dec; 7(12):6010-6019. PubMed ID: 30406969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
